Literature DB >> 29697154

A Phase-by-Phase Review of Migraine Pathophysiology.

David W Dodick1.   

Abstract

Migraine is a common, disabling neurological disorder characterized by multiple phases: premonitory, aura, headache, postdrome, and interictal. Our understanding of the pathophysiology of each phase of migraine has evolved over recent years. The premonitory phase begins as early as 3 days before the headache phase, and involves a complex interplay between various cortical and subcortical brain regions, including the hypothalamus and brainstem nuclei that modulate nociceptive signaling. The headache phase involves activation of the trigeminovascular system, a pathway that is well characterized. In one-third of patients, an aura phase may occur during some attacks and likely correlates with a cortical spreading depression-like event; a slowly propagating wave of neuronal and glial cell depolarization and hyperpolarization. Improved characterization of the pathophysiological processes involved at each stage of the migraine attack will aid the identification of new therapeutic targets for migraine prevention. This review provides an update on prevailing concepts of migraine pathophysiology.
© 2018 American Headache Society.

Entities:  

Keywords:  aura; cortical spreading depression; migraine; pathophysiology; premonitory phase; trigeminovascular pathway

Mesh:

Substances:

Year:  2018        PMID: 29697154     DOI: 10.1111/head.13300

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  48 in total

1.  Activation of Peripheral and Central Trigeminovascular Neurons by Seizure: Implications for Ictal and Postictal Headache.

Authors:  Agustin Melo-Carrillo; Aaron J Schain; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2020-06-11       Impact factor: 6.167

2.  Aberrant activity within auditory network is associated with psychiatric comorbidities in interictal migraineurs without aura.

Authors:  Heng-Le Wei; Yu-Chen Chen; Yu-Sheng Yu; Xi Guo; Gang-Ping Zhou; Qing-Qing Zhou; Li-Jie Qu; Xindao Yin; Junrong Li; Hong Zhang
Journal:  Brain Imaging Behav       Date:  2021-01-21       Impact factor: 3.978

Review 3.  Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP.

Authors:  Diana N Krause; Karin Warfvinge; Kristian Agmund Haanes; Lars Edvinsson
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

Review 4.  A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine.

Authors:  Nazir Noor; Courtney LaChute; Mathew Root; Jasmine Rogers; Madeleine Richard; Giustino Varrassi; Ivan Urits; Omar Viswanath; Nazih Khater; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-04-26

Review 5.  Headache and Autonomic Dysfunction: a Review.

Authors:  Courtney Iser; Karissa Arca
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-22       Impact factor: 6.030

6.  Association between migraine and risk of ocular motor cranial nerve palsy.

Authors:  Soolienah Rhiu; Kyungdo Han; Juhwan Yoo; Kyung-Ah Park; Sei Yeul Oh
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

7.  Vitamin D in migraine headache: a comprehensive review on literature.

Authors:  Zeinab Ghorbani; Mansoureh Togha; Pegah Rafiee; Zeynab Sadat Ahmadi; Reyhaneh Rasekh Magham; Samane Haghighi; Soodeh Razeghi Jahromi; Maryam Mahmoudi
Journal:  Neurol Sci       Date:  2019-08-03       Impact factor: 3.307

8.  Evaluation of serum uric levels in migraine.

Authors:  Tamer Yazar; Hülya Olgun Yazar; Ali Aygün; Volkan Karabacak; Yavuz Altunkaynak; Dursun Kirbaş
Journal:  Neurol Sci       Date:  2020-07-20       Impact factor: 3.307

9.  A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.

Authors:  Caroline M Kopruszinski; Edita Navratilova; Juliana Swiokla; David W Dodick; Iain P Chessell; Frank Porreca
Journal:  Cephalalgia       Date:  2020-09-26       Impact factor: 6.292

10.  Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.

Authors:  Richard B Lipton; David W Dodick; Jessica Ailani; Lora McGill; Joe Hirman; Roger Cady
Journal:  Headache       Date:  2021-05-20       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.